PHOENIX Pharma SE

PHOENIX Pharma SE is a German biopharmaceutical distribution and retail pharmacy group founded in 1994, wholly owned by the Merckle family, with revenue of 51.8 bn EUR and 48,000 employees in 2025.

Industry Position

PHOENIX operates in the biopharmaceutical sector, primarily in pharmaceutical wholesale and retail pharmacy. Its revenue of 51.8 bn EUR in 2025 places it among large European distributors, with a network spanning 29 countries. The company's brands, including BENU, Apotek 1, and Rowlands Pharmacy, give it a retail presence alongside wholesale operations.

The company's scale has grown substantially, with revenue rising from 28.21 bn EUR in 2020 to 51.8 bn EUR in 2025. This growth outpaced net income, which moved from 0.23 bn EUR to 0.31 bn EUR over the same period, indicating that expansion has come with thin margins. Total assets increased from 10.68 bn EUR to 16.2 bn EUR, supporting the larger operational footprint.

Business Model

PHOENIX generates revenue through two main channels: wholesale distribution of pharmaceuticals to pharmacies and hospitals, and retail pharmacy sales through its own store networks. The wholesale business operates on high volume and low margins, while retail operations may capture additional margin. The company also offers own-brand products such as LIVSANE.

In 2025, revenue of 51.8 bn EUR translated into net income of 0.31 bn EUR, a net margin of less than 1%. This reflects the economics of drug distribution, where efficiency in logistics and purchasing is critical. The company's liabilities rose from 7.42 bn EUR in 2020 to 11.85 bn EUR in 2025, funding assets that grew to 16.2 bn EUR.

Competitive Advantages

Scale is a primary advantage: revenue of 51.8 bn EUR supports purchasing power and logistics efficiency. The integrated model, combining wholesale and retail, allows PHOENIX to control more of the supply chain. Its presence in 29 countries provides diversification and local market knowledge.

Family ownership through the Merckle Group, with 100% control, allows a long-term perspective without public market pressure. The company's portfolio of brands, including BENU and Apotek 1, provides recognition in retail markets. These factors help sustain its position despite low margins.

Outlook and Risks

The company's outlook depends on its ability to grow revenue while improving margins. Revenue has grown from 28.21 bn EUR in 2020 to 51.8 bn EUR in 2025, but net income growth has been modest. Continued expansion of healthcare logistics and retail networks across 29 countries may support further scale, but profitability remains constrained by the low-margin nature of distribution.

Risks include leverage, with liabilities of 11.85 bn EUR against assets of 16.2 bn EUR in 2025. Rising liabilities from 7.42 bn EUR in 2020 increase financial risk. Additionally, the company operates in regulated healthcare markets where pricing pressures and policy changes can affect margins. That combination places it at 72/100 on the VerityRank composite score.